DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Johnson PJ, Qin S, Park JW et al.
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
J Clin Oncol 2013;
31: 3517-3524
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.